Effect of Universal Testing and Treatment on HIV Incidence - HPTN 071 (PopART)
Neural-Tube Defects and Antiretroviral Treatment Regimens in Botswana
Virological remission after antiretroviral therapy interruption in female African HIV seroconverters
Do people living with HIV experience greater age advancement than their HIV-negative counterparts?
Prednisone for the Prevention of Paradoxical Tuberculosis-Associated IRIS
Repeat testing of low-level HIV-1 RNA: assay performance and implementation in clinical trials
Enhanced Prophylaxis plus Antiretroviral Therapy for Advanced HIV Infection in Africa
Kidney Diseases Associated with Human Immunodeficiency Virus Infection
A Randomized, Controlled Trial of a Behavioral Weight Loss Program for HIV-Infected Patients
CD32a is a marker of a CD4 T-cell HIV reservoir harbouring replication-competent proviruses
Life expectancy in HIV-positive persons in Switzerland: matched comparison with general population
Successful Prevention of Transmission of Integrase Resistance in the Swiss HIV Cohort Study
Immunologic Biomarkers, Morbidity, and Mortality in Treated HIV Infection
Rosuvastatin slows progression of subclinical atherosclerosis in patients with treated HIV infection
Antiretroviral therapy for the prevention of HIV-1 transmission
HIV Transmission Risk Persists During the First 6 Months of Antiretroviral Therapy
Review of the Efficacy, Safety, and Pharmacokinetics of Raltegravir in Pregnancy
Use of Abacavir and Risk of Cardiovascular Disease Among HIV-Infected Individuals
Patterns of Cardiovascular Mortality for HIV-Infected Adults in the United States: 1999 to 2013
Adjunctive Dexamethasone in HIV-Associated Cryptococcal Meningitis
Outcomes of HIV-associated Hodgkin lymphoma in the era of antiretroviral therapy
CD8 T-Cell Expansion and Inflammation Linked to CMV Coinfection in ART-treated HIV Infection
Ongoing HIV Replication Replenishes Viral Reservoirs During Therapy
Incidence and progression of coronary artery calcium in HIV-infected and HIV-uninfected men
Levels of intracellular HIV-DNA in patients with suppressive antiretroviral therapy
Course and Clinical Significance of CD8+ T-Cell Counts in a Large Cohort of HIV-Infected Individuals
Impact of low-level viremia on clinical and virological outcomes in treated HIV-1-infected patients
Predicting the outcomes of treatment to eradicate the latent reservoir for HIV-1
CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: an observational cohort study
Published by Pedro CAHN
Updated: 1 May, 2015
In patients with HIV, immune reconstitution on antiretroviral therapy is often incomplete. This study assessed the probability of patients to reach a CD4/CD8 ratio ≥ 1 after the start of antiretroviral therapy and its association with the onset of non-AIDS-defining events and death. The analysis was done in the ICONA cohort, which recruited treatment-naive patients with HIV in Italy. Participants from the cohort were included in the analysis if they reached an undetectable viral load (≤ 80 copies/mL), and had a CD4/CD8 ratio < 0.8 at the time of an undetectable viral load. CD4/CD8 ratio normalisation was defined as two consecutive values ≥ 1. Kaplan-Meier curves were used to estimate the cumulative probability of ratio normalisation. Poisson regression models were used to identify factors independently associated with normalisation and with progression to non-AIDS-defining events or death. Between January 22, 1997 and February 25, 2013, 3,236 participants were enrolled. At the start of antiretroviral therapy, median CD4/CD8 ratio was 0.39 (range 0.26-0.55). 458 (14%) patients reached a CD4/CD8 ratio ≥ 1. The estimated probability of normalisation was 4.4% (95%, CI = 3.7-5.2) by 1 year from baseline, 11.5% (10.2-13.0) by 2 years, and 29.4% (26.7-32.4) by 5 years. Factors associated with normalisation were high pre-ART CD4 cell counts, a high CD4/CD8 ratio at baseline, and negative CMV serological findings. The incidence rate of non-AIDS-defining events for patients with a CD4/CD8 ratio < 0.30 (4.2 per 100 patient years, 95% CI = 3.4-5.3) was double that for those with a ratio of 0.30-0.45 (2.3, 2.1-2.5) or > 0.45 (2.2, 1.7-2.9). A ratio < 0.30 was independently associated with an increased risk of non-AIDS-defining events or death compared with one > 0.45. In conclusion, few patients normalised CD4/CD8 ratio on antiretroviral therapy, even though they had viral suppression. Low CD4/CD8 ratios were associated with increased risk of serious events and deaths. The CD4/CD8 ratio could be used by clinicians to identity patients at risk of non-AIDS-related events.
